DE10018401A1 - Verwendung von Bradycardica bei der Behandlung von mit Hypertrophie einhergehenden Myocarderkrankungen und neue Arzneimittelkombinationen - Google Patents

Verwendung von Bradycardica bei der Behandlung von mit Hypertrophie einhergehenden Myocarderkrankungen und neue Arzneimittelkombinationen

Info

Publication number
DE10018401A1
DE10018401A1 DE10018401A DE10018401A DE10018401A1 DE 10018401 A1 DE10018401 A1 DE 10018401A1 DE 10018401 A DE10018401 A DE 10018401A DE 10018401 A DE10018401 A DE 10018401A DE 10018401 A1 DE10018401 A1 DE 10018401A1
Authority
DE
Germany
Prior art keywords
cilobradine
medicament
hypertrophy
treatment
bradycardic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
DE10018401A
Other languages
German (de)
English (en)
Inventor
Juergen Daemmgen
Brian Guth
Randolph Seidler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Pharma GmbH and Co KG
Original Assignee
Boehringer Ingelheim Pharma GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma GmbH and Co KG filed Critical Boehringer Ingelheim Pharma GmbH and Co KG
Priority to DE10018401A priority Critical patent/DE10018401A1/de
Priority to SK1458-2002A priority patent/SK286075B6/sk
Priority to PCT/EP2001/004034 priority patent/WO2001078699A2/de
Priority to HU0300917A priority patent/HU228387B1/hu
Priority to NZ521934A priority patent/NZ521934A/en
Priority to ES01949281T priority patent/ES2266216T3/es
Priority to IL15210301A priority patent/IL152103A0/xx
Priority to PT01949281T priority patent/PT1276476E/pt
Priority to TR2002/02326T priority patent/TR200202326T2/xx
Priority to CZ20023752A priority patent/CZ300549B6/cs
Priority to EEP200200590A priority patent/EE05099B1/xx
Priority to US10/257,481 priority patent/US7208508B2/en
Priority to AU2001270484A priority patent/AU2001270484B2/en
Priority to CNB018079598A priority patent/CN1245963C/zh
Priority to JP2001576000A priority patent/JP3905386B2/ja
Priority to EP06111485A priority patent/EP1666042A3/de
Priority to MEP-459/08A priority patent/MEP45908A/xx
Priority to PL357827A priority patent/PL215235B1/pl
Priority to AU7048401A priority patent/AU7048401A/xx
Priority to AT01949281T priority patent/ATE330588T1/de
Priority to MXPA02009935A priority patent/MXPA02009935A/es
Priority to KR1020027013688A priority patent/KR20020089453A/ko
Priority to EP01949281A priority patent/EP1276476B1/de
Priority to BR0109996-5A priority patent/BR0109996A/pt
Priority to CA002575059A priority patent/CA2575059A1/en
Priority to EA200201053A priority patent/EA006977B1/ru
Priority to CA002404120A priority patent/CA2404120C/en
Priority to DK01949281T priority patent/DK1276476T3/da
Priority to YUP-769/02A priority patent/RS51478B/sr
Priority to SI200130616T priority patent/SI1276476T1/sl
Priority to DE50110262T priority patent/DE50110262D1/de
Priority to UA2002118949A priority patent/UA78679C2/uk
Publication of DE10018401A1 publication Critical patent/DE10018401A1/de
Priority to BG107103A priority patent/BG65816B1/bg
Priority to IL152103A priority patent/IL152103A/en
Priority to ZA200208162A priority patent/ZA200208162B/en
Priority to HRP20020815 priority patent/HRP20020815A2/hr
Priority to NO20024924A priority patent/NO330311B1/no
Priority to CY20061100956T priority patent/CY1105081T1/el
Priority to US11/684,974 priority patent/US20070155679A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE10018401A 2000-04-13 2000-04-13 Verwendung von Bradycardica bei der Behandlung von mit Hypertrophie einhergehenden Myocarderkrankungen und neue Arzneimittelkombinationen Withdrawn DE10018401A1 (de)

Priority Applications (39)

Application Number Priority Date Filing Date Title
DE10018401A DE10018401A1 (de) 2000-04-13 2000-04-13 Verwendung von Bradycardica bei der Behandlung von mit Hypertrophie einhergehenden Myocarderkrankungen und neue Arzneimittelkombinationen
PT01949281T PT1276476E (pt) 2000-04-13 2001-04-07 Utilizacao de substancias bradicardicas no tratamento de doencas do miocardio associadas a hipertrofia e novas combinacoes de medicamentos
SI200130616T SI1276476T1 (sl) 2000-04-13 2001-04-07 Uporaba bradikardnih snovi pri zdravljenju miokardnih bolezni, povezanih s hipertrofijo, in nove kombinacije zdravil
HU0300917A HU228387B1 (en) 2000-04-13 2001-04-07 Use of bradycardiac substances in the treatment of myocardial diseases associated with hypertrophy and pharmaceutical compositions containing them
NZ521934A NZ521934A (en) 2000-04-13 2001-04-07 Use of bradycardiac substances in the treatment of myocardial diseases accompanied by hypertrophy, and new drug combinations
ES01949281T ES2266216T3 (es) 2000-04-13 2001-04-07 Uso de sustancias bradicardicas en el tratamiento de enfermedades del miocardio acompañadas de hipertrofia y nuevas combinaciones de medicamentos.
IL15210301A IL152103A0 (en) 2000-04-13 2001-04-07 Use of bradycardiac substances in the treatment of myocardial diseases associated with hypertrophy and novel medicament combinations
AT01949281T ATE330588T1 (de) 2000-04-13 2001-04-07 Verwendung von bradycardica bei der behandlung von mit hypertrophie einhergehenden myocarderkrankungen und neue arzneimittelkombinationen
TR2002/02326T TR200202326T2 (tr) 2000-04-13 2001-04-07 Hipertrofi ile birlikte görülen miyokard rahatsızlıkların tedavisinde bradikardilerin kullanımı
CZ20023752A CZ300549B6 (cs) 2000-04-13 2001-04-07 Farmaceutický prostredek s obsahem cilobradinu
EEP200200590A EE05099B1 (et) 2000-04-13 2001-04-07 Bradkardiaalsete toimeainete kasutamine hpertroofiaga seotud mokardiaalsete haiguste ravimiseks ja ravimikombinatsioonid
US10/257,481 US7208508B2 (en) 2000-04-13 2001-04-07 Use of bradycardiac substances in the treatment of myocardial diseases associated with hypertrophy and novel medicament combinations
AU2001270484A AU2001270484B2 (en) 2000-04-13 2001-04-07 Use of bradycardiac substances in the treatment of myocardial diseases associated with hypertrophy and novel medicament combinations
CNB018079598A CN1245963C (zh) 2000-04-13 2001-04-07 包括心动徐缓剂的药物组合物及其用途
JP2001576000A JP3905386B2 (ja) 2000-04-13 2001-04-07 肥大を伴う心筋疾患の治療における徐脈剤の使用及び新規医薬組成物
EP06111485A EP1666042A3 (de) 2000-04-13 2001-04-07 Arzneimittelkombination enthaltend Cilobradine und eine herzwirksame Verbindung, z.B. Telmisartan
MEP-459/08A MEP45908A (en) 2000-04-13 2001-04-07 Use of bradycardiac substances in the treatment of myocardial diseases associated with hypertrophy and novel medicament combinations
PL357827A PL215235B1 (pl) 2000-04-13 2001-04-07 Kompozycja farmaceutyczna zawierajaca cylobradyne
KR1020027013688A KR20020089453A (ko) 2000-04-13 2001-04-07 비대증과 관련된 심근 질환 치료에 있어서의 서맥 물질의용도 및 신규한 약제 조성물
SK1458-2002A SK286075B6 (sk) 2000-04-13 2001-04-07 Použitie bradykardických látok a voliteľne jednejďalšej zlúčeniny pôsobiacej na srdce
MXPA02009935A MXPA02009935A (es) 2000-04-13 2001-04-07 Uso de sustancias bradicardicas para el tratamiento de enfermedades del miocardio asociadas con hipertrofia y nuevas combinaciones de medicamentos.
AU7048401A AU7048401A (en) 2000-04-13 2001-04-07 Use of bradycardiac substances in the treatment of myocardial diseases associated with hypertrophy and novel medicament combinations
EP01949281A EP1276476B1 (de) 2000-04-13 2001-04-07 Verwendung von bradycardica bei der behandlung von mit hypertrophie einhergehenden myocarderkrankungen und neue arzneimittelkombinationen
BR0109996-5A BR0109996A (pt) 2000-04-13 2001-04-07 Uso de agentes bradicardìacos no tratamento de doenças miocárdicas acompanhadas de hipertrofia, e novas combinações de drogas
CA002575059A CA2575059A1 (en) 2000-04-13 2001-04-07 Pharmaceutical compositions comprising cilobradine
EA200201053A EA006977B1 (ru) 2000-04-13 2001-04-07 Применение брадикардических средств для лечения связанных с гипертрофией заболеваний миокарда и новые комбинированные лекарственные средства
CA002404120A CA2404120C (en) 2000-04-13 2001-04-07 Use of bradycardiac agents in the treatment of myocardial diseases accompanied by hypertrophy and new drug combinations
DK01949281T DK1276476T3 (da) 2000-04-13 2001-04-07 Anvendelse af bradykardiske midler ved behandling af sygdomme i hjertemuskulaturen i forbindelse med hypertrofi, samt hedtil ukendte lægemiddelkombinationer
YUP-769/02A RS51478B (sr) 2000-04-13 2001-04-07 Upotreba bradikardijskih supstanci u lečenju miokardnih oboljenja povezanih sa hipertrofijom i nove kombinacije lekova
PCT/EP2001/004034 WO2001078699A2 (de) 2000-04-13 2001-04-07 Verwendung von bradycardica bei der behandlung von mit hypertrophie einhergehenden myocarderkrankungen und neue arzneimittelkombinationen
DE50110262T DE50110262D1 (de) 2000-04-13 2001-04-07 Verwendung von bradycardica bei der behandlung von mit hypertrophie einhergehenden myocarderkrankungen und neue arzneimittelkombinationen
UA2002118949A UA78679C2 (en) 2000-04-13 2001-07-04 Agent for treating myocardial diseases associated with hypertrophy and pharmaceutical compositions
BG107103A BG65816B1 (bg) 2000-04-13 2002-09-13 Приложение на брадикардични средства за лечение на заболявания на миокарда, съпроводени с хипертрофия
IL152103A IL152103A (en) 2000-04-13 2002-10-03 Use of bradycardic substances for the preparation of drugs for the treatment of heart disease associated with overgrowth and new drug combinations
ZA200208162A ZA200208162B (en) 2000-04-13 2002-10-10 Use of bradycardiac substances in the treatment of myocardial diseases associated with hypertrophy and novel medicament combinations.
HRP20020815 HRP20020815A2 (en) 2000-04-13 2002-10-11 Use of bradycardiac substances in the treatment of myocardial diseases associated with hypertrophy and novel medicament combinations
NO20024924A NO330311B1 (no) 2000-04-13 2002-10-11 Bradykardiale substanser for behandling av myokardiale sykdommer som ledsages av hypertrofi.
CY20061100956T CY1105081T1 (el) 2000-04-13 2006-07-07 Χρησιμοποιηση βραδυκαρδιακων ουσιων για την αγωγη των με υπepτροφια συνδεδεμενων παθησεων του μυοκαρδιου και νεοι συνδυασμοι φαρμακων
US11/684,974 US20070155679A1 (en) 2000-04-13 2007-03-12 Use of bradycardiac substances in the treatment of myocardial diseases associated with hypertrophy and novel medicament combinations

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10018401A DE10018401A1 (de) 2000-04-13 2000-04-13 Verwendung von Bradycardica bei der Behandlung von mit Hypertrophie einhergehenden Myocarderkrankungen und neue Arzneimittelkombinationen

Publications (1)

Publication Number Publication Date
DE10018401A1 true DE10018401A1 (de) 2001-10-25

Family

ID=7638652

Family Applications (2)

Application Number Title Priority Date Filing Date
DE10018401A Withdrawn DE10018401A1 (de) 2000-04-13 2000-04-13 Verwendung von Bradycardica bei der Behandlung von mit Hypertrophie einhergehenden Myocarderkrankungen und neue Arzneimittelkombinationen
DE50110262T Expired - Lifetime DE50110262D1 (de) 2000-04-13 2001-04-07 Verwendung von bradycardica bei der behandlung von mit hypertrophie einhergehenden myocarderkrankungen und neue arzneimittelkombinationen

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE50110262T Expired - Lifetime DE50110262D1 (de) 2000-04-13 2001-04-07 Verwendung von bradycardica bei der behandlung von mit hypertrophie einhergehenden myocarderkrankungen und neue arzneimittelkombinationen

Country Status (33)

Country Link
US (2) US7208508B2 (sh)
EP (2) EP1276476B1 (sh)
JP (1) JP3905386B2 (sh)
KR (1) KR20020089453A (sh)
CN (1) CN1245963C (sh)
AT (1) ATE330588T1 (sh)
AU (2) AU2001270484B2 (sh)
BG (1) BG65816B1 (sh)
BR (1) BR0109996A (sh)
CA (2) CA2575059A1 (sh)
CY (1) CY1105081T1 (sh)
CZ (1) CZ300549B6 (sh)
DE (2) DE10018401A1 (sh)
DK (1) DK1276476T3 (sh)
EA (1) EA006977B1 (sh)
EE (1) EE05099B1 (sh)
ES (1) ES2266216T3 (sh)
HR (1) HRP20020815A2 (sh)
HU (1) HU228387B1 (sh)
IL (2) IL152103A0 (sh)
ME (1) MEP45908A (sh)
MX (1) MXPA02009935A (sh)
NO (1) NO330311B1 (sh)
NZ (1) NZ521934A (sh)
PL (1) PL215235B1 (sh)
PT (1) PT1276476E (sh)
RS (1) RS51478B (sh)
SI (1) SI1276476T1 (sh)
SK (1) SK286075B6 (sh)
TR (1) TR200202326T2 (sh)
UA (1) UA78679C2 (sh)
WO (1) WO2001078699A2 (sh)
ZA (1) ZA200208162B (sh)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10018401A1 (de) 2000-04-13 2001-10-25 Boehringer Ingelheim Pharma Verwendung von Bradycardica bei der Behandlung von mit Hypertrophie einhergehenden Myocarderkrankungen und neue Arzneimittelkombinationen
DE60200160T2 (de) * 2002-07-25 2004-11-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von Cilobradine oder pharmazeutisch akzeptablen Salze zur Behandlung oder Prävention von Herzversagen
US20040138306A1 (en) * 2002-07-25 2004-07-15 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of a specific cyclic amine derivative or the pharmaceutically acceptable salts thereof for the treatment or prevention of heart failure
NZ541454A (en) 2003-01-31 2008-04-30 Daiichi Sankyo Co Ltd Medicine for prevention of and treatment for arteriosclerosis and hypertension
WO2007001066A1 (en) * 2005-06-27 2007-01-04 Daiichi Sankyo Company, Limited Pharmaceutical preparation containing an angiotensin ii receptor antagonist and a calcium channel blocker
WO2007023775A1 (ja) * 2005-08-23 2007-03-01 Astellas Pharma Inc. 心房細動治療剤
EP1762179A1 (en) * 2005-09-07 2007-03-14 Boehringer Ingelheim Vetmedica Gmbh Method for improving diagnostic quality in echocardiography
FR2894825B1 (fr) * 2005-12-21 2010-12-03 Servier Lab Nouvelle association d'un inhibiteur du courant if sinusal et d'un inhibiteur de l'enzyme de conversion et les compositions pharmaceutiques qui la contiennent
TWI399223B (zh) * 2006-09-15 2013-06-21 Daiichi Sankyo Co Ltd 奧美沙坦酯及氨氯地平之固體劑型
EP1908469A1 (en) 2006-10-06 2008-04-09 Boehringer Ingelheim Vetmedica Gmbh Angiotensin II receptor antagonist for the treatment of systemic diseases in cats
WO2010133638A1 (de) 2009-05-20 2010-11-25 Boehringer Ingelheim Vetmedica Gmbh Pharmazeutische telmisartan-trinklösung
FR2961105B1 (fr) * 2010-06-15 2013-02-08 Servier Lab Utilisation de l'association d'un inhibiteur du courant if sinusal et d'un inhibiteur de l'enzyme de conversion de l'angiotensine pour le traitement de l'insuffisance cardiaque
KR101296743B1 (ko) * 2011-02-17 2013-08-20 한국과학기술연구원 심근 비대증 진단용 바이오마커 및 이를 이용한 심근 비대증 진단 방법
RU2014109079A (ru) 2011-08-12 2015-09-20 Бёрингер Ингельхайм Ветмедика Гмбх Фармацевтическая композиция с маскированным вкусом
EP2953612A1 (en) 2013-02-11 2015-12-16 Boehringer Ingelheim Vetmedica GmbH Kit-of-parts
US10905676B2 (en) 2017-07-07 2021-02-02 Boehringer Ingelheim Vetmedica Gmbh Angiotensin II receptor antagonist for the prevention or treatment of systemic diseases in cats
KR102331806B1 (ko) 2020-07-20 2021-12-01 한림대학교 산학협력단 중증 지주막하출혈 진단용 바이오 마커
KR102398532B1 (ko) 2020-07-20 2022-05-13 한림대학교 산학협력단 중증 지주막하출혈 진단용 조성물

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE759125A (fr) 1969-11-19 1971-05-18 Boehringer Sohn Ingelheim Nouvelles n-allyl-2-arylamino-imidazolines-(2) substituees et procedes pour les fabriquer
DE3119874A1 (de) 1981-05-19 1982-12-09 Dr. Karl Thomae Gmbh, 7950 Biberach "benzazepinderivate, ihre herstellung und ihre verwendung als arzneimittel"
US5175157A (en) * 1985-11-27 1992-12-29 Boehringer Ingelheim Gmbh Cyclic amine derivatives, pharmaceutical compositions containing these compounds and methods for preparing them
DE3541811A1 (de) * 1985-11-27 1987-06-04 Thomae Gmbh Dr K Neue cyclische aminderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
DE3736866A1 (de) * 1987-10-30 1989-05-11 Thomae Gmbh Dr K Mittel zur behandlung des bluthochdrucks und der herzinsuffizienz
DE3805635A1 (de) 1988-02-24 1989-09-07 Thomae Gmbh Dr K Verwendung von benzimidazolen zur herstellung eines arzneimittels mit antiischaemischen wirkungen am herzen und dessen kombinationen mit ss-blockern oder bradycardica
US5308853A (en) * 1991-12-20 1994-05-03 Warner-Lambert Company Substituted-5-methylidene hydantoins with AT1 receptor antagonist properties
RU2078536C1 (ru) * 1993-09-02 1997-05-10 Украинский научно-исследовательский институт кардиологии им.акад.Н.Д.Стражеско Способ определения клинической эффективности применения верапамила и дилтиазема у больных гипертрофической кардиомиопатией
BR9407613A (pt) * 1993-09-24 1997-01-14 Procter & Gamble Novos compostos deoxi e 14-amino esteróide contendo açúcar substituído com oxigênio
US5595987A (en) * 1994-07-22 1997-01-21 The Trustees Of Columbia University In The City Of New York Method of slowing ventricular arrhythmias using zatebradine
US6083991A (en) * 1997-06-04 2000-07-04 University Of Florida Research Foundation, Inc. Anti-arrhythmic composition and methods of treatment
DE19741635A1 (de) * 1997-09-22 1999-03-25 Hoechst Marion Roussel De Gmbh Biphenylsulfonylcyanamide, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament
EP1870098A3 (en) 1998-07-10 2010-07-07 Novartis Ag Combined use of valsartan and calcium channel blockers for therapeutic purposes
DE10018401A1 (de) * 2000-04-13 2001-10-25 Boehringer Ingelheim Pharma Verwendung von Bradycardica bei der Behandlung von mit Hypertrophie einhergehenden Myocarderkrankungen und neue Arzneimittelkombinationen
US20040138306A1 (en) * 2002-07-25 2004-07-15 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of a specific cyclic amine derivative or the pharmaceutically acceptable salts thereof for the treatment or prevention of heart failure
CA2435526A1 (en) 2002-07-25 2004-01-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of cyclic amine derivatives or the pharmaceutically acceptable salts thereof for the treatment or prevention of heart failure
EP1762179A1 (en) * 2005-09-07 2007-03-14 Boehringer Ingelheim Vetmedica Gmbh Method for improving diagnostic quality in echocardiography

Also Published As

Publication number Publication date
SI1276476T1 (sl) 2006-10-31
EP1276476A2 (de) 2003-01-22
DE50110262D1 (de) 2006-08-03
IL152103A0 (en) 2003-07-31
CA2575059A1 (en) 2001-10-25
SK14582002A3 (sk) 2003-03-04
CA2404120A1 (en) 2001-10-25
EA006977B1 (ru) 2006-06-30
CA2404120C (en) 2008-01-22
EP1666042A3 (de) 2006-06-21
EA200201053A1 (ru) 2003-02-27
JP2003535050A (ja) 2003-11-25
MEP45908A (en) 2011-02-10
NO330311B1 (no) 2011-03-28
AU2001270484B2 (en) 2007-01-25
KR20020089453A (ko) 2002-11-29
ES2266216T3 (es) 2007-03-01
PL357827A1 (en) 2004-07-26
NO20024924L (no) 2002-10-11
EP1276476B1 (de) 2006-06-21
UA78679C2 (en) 2007-04-25
PL215235B1 (pl) 2013-11-29
AU7048401A (en) 2001-10-30
CZ20023752A3 (cs) 2003-03-12
DK1276476T3 (da) 2006-08-14
CN1422153A (zh) 2003-06-04
CN1245963C (zh) 2006-03-22
EP1666042A2 (de) 2006-06-07
US7208508B2 (en) 2007-04-24
CY1105081T1 (el) 2009-11-04
ATE330588T1 (de) 2006-07-15
BG65816B1 (bg) 2010-01-29
US20040014795A1 (en) 2004-01-22
BG107103A (bg) 2003-04-30
PT1276476E (pt) 2006-09-29
HRP20020815A2 (en) 2004-12-31
EE200200590A (et) 2004-04-15
JP3905386B2 (ja) 2007-04-18
NZ521934A (en) 2007-05-31
WO2001078699A3 (de) 2002-06-20
YU76902A (sh) 2006-05-25
WO2001078699A2 (de) 2001-10-25
EE05099B1 (et) 2008-12-15
US20070155679A1 (en) 2007-07-05
SK286075B6 (sk) 2008-03-05
HUP0300917A3 (en) 2009-04-28
TR200202326T2 (tr) 2003-03-21
RS51478B (sr) 2011-04-30
BR0109996A (pt) 2003-05-27
HUP0300917A2 (hu) 2003-08-28
MXPA02009935A (es) 2003-02-12
IL152103A (en) 2008-07-08
NO20024924D0 (no) 2002-10-11
HU228387B1 (en) 2013-03-28
ZA200208162B (en) 2003-10-17
CZ300549B6 (cs) 2009-06-10

Similar Documents

Publication Publication Date Title
EP1276476B1 (de) Verwendung von bradycardica bei der behandlung von mit hypertrophie einhergehenden myocarderkrankungen und neue arzneimittelkombinationen
DE60117295T2 (de) Synergistische kombinationen mit einem renin-inhibitor für kardiovaskuläre erkrankungen
DE60109589T2 (de) Pharmazeutische zusammensetzung zur behandlung von akutem schmerz, chronischem schmerz und/oder neuropathischem schmerz und migräne
DE69814850T2 (de) Paracetamol enthaltende schlickbare tablette
EP1056448B1 (de) Pharmazeutische kombinationen mit tramadol
DE60030654T2 (de) Verwendung von Lasofoxifen
DE60200160T2 (de) Verwendung von Cilobradine oder pharmazeutisch akzeptablen Salze zur Behandlung oder Prävention von Herzversagen
DE69529819T2 (de) Neue kombination eines betablockers mit einem lokalanästhetikum
WO2003099265A2 (de) Pharmazeutische wirkstoffkombination sowie deren verwendung
EP0471388B1 (de) Mittel zur Behandlung der Herzinsuffizienz
WO1999016444A1 (de) Endothelin-antagonist und betarezeptorenblocker als kombinationspräparate
DE2126035A1 (de) Neue pharmazeutische Zusammensetzung
DE602004012593T2 (de) Kombinationen aus valsartan, amilorid oder triamterin und einem diuretikum
DE2823268C2 (sh)
CH649918A5 (de) Verwendung von n-amidino-2-phenylacetamiden als wirkstoff zur herstellung von pharmazeutischen zubereitungen gegen schizophrenie.
DE2823267C2 (sh)
DE69923982T2 (de) Verwendung einer zusammensetzung enthaltend eine assoziation eines angiotensin ii at1 rezeptor antagonists und indomethacin zur herstellung eines arzneimittels zur behandlung von kronischen glomerulonephriten
DE1804634A1 (de) Neue pharmazeutische Zusammensetzung
DE2636328A1 (de) Arzneimittel
DE69832075T2 (de) Verwendung von eprosartan zur behandlung von isoliertem systolischem bluthochdrucks
EP1474134B1 (de) Kombinationspräparat des natrium-wasserstoff-austausch-inhibitors cariporide mit ramipril zur verhinderung bzw zur hemmung der herzinsuffizienz
DE3800868A1 (de) Mittel zur behandlung von bradycardien und bradyarrhythmien
DE2805165A1 (de) Gitoxin enthaltendes arzneimittel und verfahren zu seiner herstellung
WO1999017756A2 (de) Methode zur verhinderung der transplantatabstossung
DE2505913A1 (de) Arzneimittel zur oralen behandlung von nicht-tumorartigen gastroduodenalbeschwerden und verfahren zu seiner herstellung

Legal Events

Date Code Title Description
8127 New person/name/address of the applicant

Owner name: BOEHRINGER INGELHEIM PHARMA GMBH & CO.KG, 55218 IN

8141 Disposal/no request for examination